Intercept pharmaceuticals

Home > Genextra Group > Intercept

Bile Acids Therapeutics

Intercept Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Founded by Dr. Mark Pruzanski in 2002, Intercept's science is based on the recent discovery that bile acids act as complex signaling molecules involved in the maintenance of lipid and glucose homeostasis, while also preserving functional integrity of the liver and other organs. The company's current drug development programs are focused on modulating bile acid receptors with an initial focus on amelioration of metabolic and hepatic function in chronic liver diseases.
Intercept's core technology was developed by leading bile acid researchers at the University of Perugia in Italy, where a team of medicinal chemists and molecular biologists conduct drug discovery research for the company.
The company has raised approximately $45 million from private investors including Milan-based Genextra S.p.A., New York-based Visium and JAFCO Life Science Investment in Tokyo.

For more information on Intercept Pharmaceutical's scientific programs visit us at
www.interceptpharma.com